Related Experiment Video
Updated: Jan 18, 2026
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Study of angiogenic cell therapy for progressive pulmonary arterial hypertension: intervention with repeat dosing of
Duncan J Stewart1, Sanjay Mehta2, George Chandy3
1Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Department of Cell and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Abstract:
Pulmonary arterial hypertension (PAH) is characterized by widespread pruning of the distal pulmonary arterial bed, leading to increased pulmonary vascular resistance, right heart failure, and death. PAH patients receiving background therapy were randomized to receive a course of 4 monthly infusions of placebo or angiogenic endothelial progenitor cells (EPCs) transfected with endothelial NO synthase (eNOS) over the first 6-month period for a cumulative dose of 80 M cells. Due to the COVID-19 pandemic, the trial was stopped after 12 of the planned 45 patients were enrolled (five placebo, seven eNOS-EPCs). While the small sample size precluded appropriately powered analyses, a possible difference was seen in 6MWD between the eNOS-EPC and placebo groups over 6 months, with a greater proportion of patients in the cell therapy group achieving a minimal clinically important increase in 6MWD of 33-m (71.4% vs 40%, respectively). Treatment of PAH patients with a course of 4 monthly infusions of eNOS-EPCs was well tolerated and may have resulted in clinical benefit.
More Related Videos
11:49Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
Published on: September 9, 2011
07:45Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization
Published on: January 23, 2019
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:24Regulation of Angiogenesis and Blood Supply